Spyglass Pharma, Inc. (SGP) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Spyglass Pharma, Inc. (SGP) stock forecast summary
On Oct. 16, 2026, SGP is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Spyglass Pharma, Inc. is a small-cap company with a market capitalization of $803M. It ranks number 40 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast. Its Current Ratio of 25.06x is the highest of the 59 peers that report one. Its D/E Ratio of 0.05x is the lowest of the 56 peers that report one.
For SGP, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 55.0%, measured on 82 forecast dates between 2026-03-26 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 125 forecast dates between 2026-03-26 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SGP included.
Follow SGP freeSGP price chart and AI forecast
How SGP ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Spyglass Pharma, Inc. (SGP) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | SGP | Rank |
|---|---|---|
| Market Cap | $803M | 40/60 |
| P/B Ratio | 3.45x | 34/55 |
| Book Value/Share | $6.95 | – |
Financial Health
| Metric | SGP | Rank |
|---|---|---|
| Current Ratio | 25.06x | 1/59 |
| D/E Ratio | 0.05x | 56/56 |
| Financial Leverage | 1.05x | 54/54 |
| Working Capital | $227M | 30/59 |
Dividend & Shareholder Information
| Metric | SGP | Rank |
|---|---|---|
| Shares Outstanding | 33M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $236M | 97.0% of assets |
| Cash & Short-term Investments | $223M | 91.5% of assets |
| Total Liabilities | $11M | 4.5% of assets |
| Short-term Debt | $5M | 2.2% of assets |
SGP quarterly financials and insider trading
Spyglass Pharma, Inc. (SGP) industry peers
Companies classified under the same SEC industry code as Spyglass Pharma, Inc. (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SGP Spyglass Pharma, Inc. | ▶ | $803M |
| SYK Stryker Corp | ▼ | $113.02B |
| MMM 3m Co | ▶ | $84.97B |
| BSX Boston Scientific Corp | ▼ | $64.33B |
| BDX Becton Dickinson & Co | ▼ | $52.23B |
| MDLN Medline Inc. | ▶ | $47.28B |
| RMD Resmed Inc | ▼ | $34.47B |
| DXCM Dexcom Inc | ▼ | $32.47B |
| WST West Pharmaceutical Services Inc | ▼ | $27.03B |
| SOLV Solventum Corp | ▼ | $14.61B |
| BAX Baxter International Inc | ▼ | $13.07B |
| PEN Penumbra Inc | ▼ | $12.64B |
| GMED Globus Medical Inc | ▼ | $10.30B |
| PODD Insulet Corp | ▼ | $9.79B |
| GKOS Glaukos Corp | ▲ | $9.72B |
| TFX Teleflex Inc | ▼ | $5.53B |
| HAE Haemonetics Corp | ▶ | $5.38B |
| MMSI Merit Medical Systems Inc | ▼ | $5.33B |
| STVN Stevanato Group S.P.A. | ▲ | $5.16B |
| MMED Minimed Group, Inc. | ▲ | $4.92B |
| HTFL Heartflow, Inc. | ▲ | $4.20B |
| ICUI Icu Medical Inc/De | ▼ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.58B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.17B |
| ATRC Atricure, Inc. | ▲ | $2.85B |
| UFPT Ufp Technologies Inc | ▼ | $2.26B |
| INSP Inspire Medical Systems, Inc. | ▲ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▶ | $1.85B |
| NVCR Novocure Ltd | ▲ | $1.64B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.62B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.62B |
| DRTS Alpha Tau Medical Ltd. | ▶ | $1.16B |
| TNDM Tandem Diabetes Care Inc | ▲ | $1.13B |
| IRMD Iradimed Corp | ▶ | $1.13B |
| AORT Artivion, Inc. | ▶ | $1.06B |
| IART Integra Lifesciences Holdings Corp | ▶ | $1.03B |
| PRCT Procept Biorobotics Corp | ▲ | $1.01B |
| BVS Bioventus Inc. | ▶ | $908M |
| SIBN Si-Bone, Inc. | ▶ | $882M |
| BBNX Beta Bionics, Inc. | ▲ | $863M |
| MDXG Mimedx Group, Inc. | ▲ | $646M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| SSII Ss Innovations International, Inc. | ▲ | $517M |
| TCMD Tactile Systems Technology Inc | ▼ | $510M |
| DCTH Delcath Systems, Inc. | ▲ | $497M |
| ANGO Angiodynamics Inc | ▲ | $473M |
| SGHT Sight Sciences, Inc. | ▲ | $456M |
| BWAY Brainsway Ltd. | ▶ | $448M |
| CERS Cerus Corp | ▶ | $439M |
| NPCE Neuropace Inc | ▶ | $420M |
| RCEL Avita Medical, Inc. | ▲ | $403M |
| OFIX Orthofix Medical Inc. | ▼ | $382M |
| CARL Carlsmed, Inc. | ▲ | $366M |
| EMBC Embecta Corp. | ▶ | $355M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $328M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $277M |
| MOBI Mobia Medical, Inc. | ▼ | $269M |
| ANIK Anika Therapeutics, Inc. | ▶ | $267M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $252M |
| OSUR Orasure Technologies Inc | ▲ | $249M |
Where SGP sits on the market map
Spyglass Pharma, Inc. (SGP) stock news
Loading...
Spyglass Pharma, Inc. (SGP) stock forecast FAQ
What is the Spyglass Pharma, Inc. (SGP) stock forecast?
On Oct. 16, 2026, SGP is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Spyglass Pharma, Inc. stock predictions?
For SGP, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 55.0%, measured on 82 forecast dates between 2026-03-26 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 125 forecast dates between 2026-03-26 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Spyglass Pharma, Inc. forecasts updated?
Spyglass Pharma, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Spyglass Pharma, Inc.'s industry peers?
60 issuers in our coverage, SGP included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.